Altimmune (NASDAQ:ALT) Receives “Buy” Rating from B. Riley

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research note issued to investors on Thursday, Benzinga reports. They currently have a $20.00 target price on the stock. B. Riley’s price target would indicate a potential upside of 93.61% from the company’s previous close.

Several other equities research analysts have also weighed in on the company. The Goldman Sachs Group initiated coverage on Altimmune in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $13.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Altimmune in a research report on Friday, December 1st.

Altimmune Trading Up 16.2 %

ALT traded up $1.44 on Thursday, hitting $10.33. 4,547,882 shares of the stock traded hands, compared to its average volume of 5,998,289. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84. The firm has a market capitalization of $555.03 million, a PE ratio of -6.64 and a beta of 0.08. The business has a fifty day moving average price of $9.92 and a two-hundred day moving average price of $6.69.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Osaic Holdings Inc. increased its position in shares of Altimmune by 77.3% in the 2nd quarter. Osaic Holdings Inc. now owns 7,834 shares of the company’s stock valued at $28,000 after buying an additional 3,416 shares in the last quarter. WealthPlan Investment Management LLC acquired a new stake in Altimmune in the 3rd quarter valued at about $31,000. FNY Investment Advisers LLC acquired a new stake in Altimmune in the 4th quarter valued at about $35,000. Keudell Morrison Wealth Management acquired a new stake in Altimmune in the 3rd quarter valued at about $36,000. Finally, Brave Asset Management Inc. acquired a new stake in Altimmune in the 3rd quarter valued at about $39,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.